Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.
暂无分享,去创建一个
Margaret A Goodell | Cliona M Rooney | C. Rooney | M. Goodell | L. Brunetti | Daisuke Nakada | Michael C Gundry | Lorenzo Brunetti | Angelique Lin | Allison E Mayle | Ayumi Kitano | Dimitrios Wagner | Joanne I Hsu | Kevin A Hoegenauer | Daisuke Nakada | Allison Mayle | A. Lin | D. Wagner | A. Kitano | Joanne I. Hsu | Michael C. Gundry | Kevin A. Hoegenauer
[1] Steven Lin,et al. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery , 2014, eLife.
[2] W. Alexander,et al. Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis. , 2015, Blood.
[3] Daesik Kim,et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.
[4] S. Orkin,et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. , 2014, Cell stem cell.
[5] J. Doudna,et al. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.
[6] Nathan C Boles,et al. Less is more: unveiling the functional core of hematopoietic stem cells through knockout mice. , 2012, Cell stem cell.
[7] Alexandro E. Trevino,et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex , 2014, Nature.
[8] M. Wunderlich,et al. Xenograft models for normal and malignant stem cells. , 2015, Blood.
[9] Michel Sadelain,et al. Hematopoietic stem cell engineering at a crossroads. , 2012, Blood.
[10] G. Sauvageau,et al. A Functional Screen to Identify Novel Effectors of Hematopoietic Stem Cell Activity , 2008, Cell.
[11] O. Abdel-Wahab,et al. The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.
[12] E. Lander,et al. Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.
[13] B. van Steensel,et al. Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.
[14] P. Marrack,et al. Observation of antigen-dependent CD8+ T-cell/ dendritic cell interactions in vivo. , 2001, Cellular immunology.
[15] Luke A. Gilbert,et al. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.
[16] David Bryder,et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. , 2014, Cell stem cell.
[17] Robert Langer,et al. CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling , 2014, Cell.
[18] M. van der Burg,et al. Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.
[19] Aviv Regev,et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing , 2014, Nature Biotechnology.
[20] J. Dick,et al. Comparison of human cord blood engraftment between immunocompromised mouse strains. , 2010, Blood.
[21] Yongxiang Zhao,et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system , 2013, Nature Biotechnology.
[22] Charles E. Vejnar,et al. CRISPRscan: designing highly efficient sgRNAs for CRISPR/Cas9 targeting in vivo , 2015, Nature Methods.
[23] Jennifer A. Doudna,et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins , 2015, Proceedings of the National Academy of Sciences.
[24] Cameron S. Osborne,et al. LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.
[25] Lei Zhang,et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. , 2015, Blood.
[26] Jacob E Corn,et al. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA , 2016, Nature Biotechnology.
[27] G. Sauvageau,et al. An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity. , 2010, Cell stem cell.
[28] Israel Steinfeld,et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.
[29] Castle Raley,et al. Targeted Gene Addition to a Safe Harbor locus in human CD34+ Hematopoietic Stem Cells for Correction of X-linked Chronic Granulomatous Disease , 2016, Nature Biotechnology.
[30] J. Doudna,et al. Expanding the Biologist's Toolkit with CRISPR-Cas9. , 2015, Molecular cell.